Item 5.07 Submission of Matters to a Vote of Security Holders.

On March 14, 2023, Summit Healthcare Acquisition Corp., an exempted company incorporated with limited liability under the laws of Cayman Islands ("Summit") held an extraordinary general meeting of shareholders (the "Extraordinary General Meeting"). At the Extraordinary General Meeting, a total of 15,865,381 (approximately 61.61%) of Summit's issued and outstanding ordinary shares (the "Summit Shares") held of record as of February 2, 2023, the record date for the Extraordinary General Meeting, were present either in person or by proxy, which constituted a quorum for the transaction of business.

Summit's shareholders voted on the following proposals at the Extraordinary General Meeting, in each case as defined and described in greater detail in the definitive proxy statement/final prospectus filed with the U.S. Securities Exchange Commission (the "SEC") on February 8, 2023 (as supplemented, amended or updated from time to time, the "Proxy Statement/Prospectus").

Capitalized terms not otherwise defined herein have the same meanings ascribed to them in the Proxy Statement/Prospectus.

Proposal No. 1 - The Business Combination Proposal - The approval of this proposal required an ordinary resolution under Cayman Islands law and the Summit Articles, being the affirmative vote of the holders of a majority of the issued and outstanding Summit Shares present in person physically or by virtual attendance or represented by proxy and entitled to vote at the Extraordinary General Meeting. The Business Combination Proposal was approved. The voting results of the Summit Shares were as follows:





For        Against   Abstain
13,435,758 2,429,219 404

Proposal No. 2 - The Merger Proposal - The approval of this proposal required a special resolution under Cayman Islands law and the Summit Articles, being the affirmative vote of the holders of at least two-thirds of the issued and outstanding Summit Shares present in person physically or by virtual attendance or represented by proxy and entitled to vote at the Extraordinary General Meeting. The Merger Proposal was approved. The voting results of the Summit Shares were as follows:





For        Against   Abstain
13,435,758 2,429,219 404

Proposal No. 3 - The Adjournment Proposal - This proposal was not presented at the Extraordinary General Meeting, as each of the other Proposals received a sufficient number of votes for approval.

Item 7.01 Regulation FD Disclosure.

On March 14, 2023, Summit and YS Biopharma issued a joint press release announcing the approval of the Business Combination and other related proposals by Summit's shareholders. A copy of the joint press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report").

The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of Summit under the Securities Act of 1933, as amended (the "Securities Act") or the Exchange Act, regardless of any general incorporation language in such filings.




Item 8.01 Other Events.

19,388,769 Summit Shares were redeemed in connection with the Extraordinary General Meeting. Based on such results, the "Redemption Rate" is 96.9% and the "Summit Class A Exchange Ratio" is 1.4286 for the purposes of the Business Combination, as such terms are defined in the Proxy Statement/Prospectus.

Based on the results of the Extraordinary General Meeting, and subject to the satisfaction or waiver of certain other closing conditions as described in the Proxy Statement/Prospectus, the Business Combination and other transactions contemplated by the Business Combination Agreement is expected to be consummated on March 16, 2023. Following the consummation of the Business Combination, the ordinary shares and warrants of YS Biopharma are expected to begin trading on the Nasdaq Capital Market under the symbols "YS" and "YSBPW," respectively, on March 17, 2023.

© Edgar Online, source Glimpses